GLOBAL CELL THERAPY MANUFACTURING EQUIPMENT MARKET (2026 - 2030)
In 2025, the Cell Therapy Manufacturing Equipment Market was valued at approximately USD 3.45 billion. It is projected to grow at a CAGR of around 14.6% during the forecast period of 2026–2030, reaching an estimated USD 6.82 billion by 2030.
Global Cell Therapy Manufacturing Equipment Markets turn out to be the ecosystem of the specific systems that are used to modify the living cells into treatment products during the multi-stage production procedures. It covers instruments that allow isolating, growing, altering, storing, and ultimately preparing cells to be utilized by patients. Precision, sterility, and reproducibility are key attributes of success in the market, which is a critical layer of the cell therapy value chain. It is not only influenced by technological innovation but also by the changing requirements of the clinical and commercial scale production.
The market encompasses capital equipment that is used in cell processing processes, including upstream handling, downstream preparation, and storage. It does not consider consumables, reagents, contract services, or the therapeutic products themselves, but only equipment sales. This limit provides a demarcation in the attribution of revenues and prevents overlaps with other neighboring markets. Customers usually consider the consistency of performance, integration, and readiness to comply with the systems, as opposed to the specifications taken separately.
The situation is changing to an integrated, automated, and closed landscape as opposed to a fragmented, manual landscape. Therapy in its non-clinical phase is increasingly often standardized and scalable. The emergence of allogeneic methods and growing commercial grants are driving the demand for high throughput and process reliability. Meanwhile, the complexity of operation is rising, and it needs much tighter control between the interlinked steps.
Key Market Insights
Research Methodology
Scope & Definitions
Evidence Collection (Primary + Secondary)
Triangulation & Validation
Presentation & Auditability
Cell Therapy Manufacturing Equipment Market Drivers
Quickening Cell Therapy Pipeline and Clinical Translation.
The market is also being intensely motivated by the ongoing boom of cell therapy pipelines in oncology, rare diseases, and regenerative medicine. There is an increasing trend of treatments that are not in the preclinical phase of their development going to late-stage clinical trials and, in a few cases, commercial development. This shift is not merely a growing demand; it is altering the nature of the equipment in demand. Small, flexible setups are common in starting programs, but as programs scale, a distinct transition is made to scalable, standardized platforms that are able to maintain a consistent output.
Move to More Automation and a Closed System.
Manufacturers are reacting by embracing semi-automated and fully automated systems that minimize the involvement of human beings and enhance reproducibility. Special focus is put on closed systems, which reduce contact with the outside world, which proves critical in preserving the integrity of the products. This change is, however, not simply a technological one—it is a strategic change. Organizations are coming to realize that automation is not only about efficiency but also about scale, failure rates, and regulatory compliance.
Growing Importance of Outsourcing and Specialist Manufacturing Infrastructure.
Another important driver that is influencing the market is the increased dependence on contract development and manufacturing organizations. Not every developer of the therapy has the means and know-how to construct and manage the complex manufacturing plants. Consequently, they are resorting to specialized partners, which have the ability to offer end-to-end production.
Cell Therapy Manufacturing Equipment Market Restraints
High capital costs and unpredictable scale economics are the long-term irritants in the market. Most systems can perform very well at the early stages, but fail on the commercial transition. Operational complexity is caused by process variability, low levels of standardization, and inter-equipment layer integration. The regulatory demands keep changing to impose a compliance burden and extend the process of validation.
Cell Therapy Manufacturing Equipment Market Opportunities
The Global Cell Therapy Manuf. The equipment market is providing new opportunities as developers drive towards scalable and standardized production. The increase in the need to have automated and closed systems implies the possibilities of equipment enhancing consistency and minimizing the risk of contamination. Growth of commercial production promotes the necessity to have high-throughput platforms, whereas new markets invest in domestic production. Innovation is also progressing faster through strategic collaborations between equipment and therapy developers.
How this market works end-to-end
Therapy developers define whether the process is autologous or allogeneic, which shapes equipment needs.
Cell collection and initial processing systems are selected to isolate and prepare starting material.
Expansion platforms, often bioreactors, are chosen based on scale, yield, and control requirements.
Separation and sorting equipment refine cell populations to meet therapy specifications.
Fill-finish systems prepare final doses in sterile, controlled environments.
Cryopreservation equipment enables storage, transport, and inventory management.
Teams decide between manual, semi-automated, or fully automated closed systems.
Scale shifts from clinical to commercial manufacturing, requiring different throughput and reliability.
Equipment integration across steps becomes critical to avoid process bottlenecks.
End users, including biopharma firms and CDMOs, validate systems against regulatory and operational standards.
What matters most when evaluating claims in this market
|
Claim type |
What good proof looks like |
What often goes wrong |
|
Scalability |
Demonstrated performance at commercial batch sizes |
Tested only at lab or pilot scale |
|
Automation |
Clear reduction in manual steps and error rates |
Automation adds complexity without efficiency |
|
Closed system |
Validated contamination control data |
Partial closure marketed as fully closed |
|
Yield improvement |
Reproducible, multi-batch data |
One-off results presented as standard |
|
Integration |
Seamless workflow across multiple steps |
Requires manual intervention between systems |
The decision lens
The contrarian view
Many buyers assume automation is always better. It is not. Over-automation can lock processes too early and increase cost without improving outcomes. Another common mistake is treating clinical-scale success as proof of commercial viability. These are different problems.
Vendors often present “closed systems” that still rely on manual interventions between steps. This creates hidden contamination risks.
Double counting also occurs when buyers evaluate systems independently rather than as part of a workflow. A high-performing bioreactor means little if fill-finish becomes the bottleneck.
One-size-fits-all solutions rarely work. Autologous workflows demand flexibility, while allogeneic setups prioritize scale and consistency. Mixing these assumptions leads to poor investment decisions.
Practical implications by stakeholder
GLOBAL CELL THERAPY MANUFACTURING EQUIPMENT MARKET
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2024 - 2030 |
|
Base Year |
2024 |
|
Forecast Period |
2025 - 2030 |
|
CAGR |
14.6% |
|
Segments Covered |
By Product, Type, Consumption, Distribution Channel and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regional Scope |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Key Companies Profiled |
Thermo Fisher Scientific Inc. , Sartorius AG Danaher Corporation , Merck KGaA Lonza Group AG , Eppendorf AG , Getinge AB , Cytiva (Danaher Corporation) , Miltenyi Biotec , Fresenius Kabi AG , Terumo Corporation , BD (Becton, Dickinson and Company) , Bio-Techne Corporation Avantor, Inc. , Corning Incorporated |
Cell Therapy Manufacturing Equipment Market Segmentation
Cell Therapy Manufacturing Equipment Market – By Equipment Type
Cell Processing Systems, with the highest share of 28%, is the backbone of the operations in the entire workflow, and Cell Expansion & Bioreactor Systems, with the highest growth rate of 24 percent, is the most expanding one because of the rising scale needs. Separation equipment contains 18%. fill-finish 13%. cryopreservation, 11. and others 6.
The highest growth is also seen in Cell Expansion & Bioreactor Systems, with 24% growth since there is the increasing demand for scalable and controlled conditions, whereas Cell Processing Systems, with 28%, continue to be the dominant ones because of the universal applications across both initial and commercial manufacturing configurations worldwide.
Cell Therapy Manufacturing Equipment Market – By Therapy Type
Cell Therapy Manufacturing Equipment Market – By Scale of Operation
Cell Therapy Manufacturing Equipment Market – By Level of Automation
Semi-automated systems, with the highest share of 38%, are the most flexible and efficient, with fully automated and closed systems at 34% and the highest growth rate of 17.5%, respectively, because of the advantage of sterility and reproducibility. Manual systems have 20 percent, and others have 8 percent.
Fully automated systems and closed systems are the most rapidly growing, with 34 and 38 percent growth, with the help of contamination control benefits and lower costs of start-up and adaptability to various production settings.
Cell Therapy Manufacturing Equipment Market – By End User
Cell Therapy Manufacturing Equipment Market – Regional Analysis
North America takes up the largest share of 39% due to the high manufacturing infrastructure, and Asia Pacific, Europe, South America, and the Middle East and Africa share 26%, 22%, 7%, and 6%, respectively.
Asia Pacific, with a growth of 26, and North America, at 39, are the fastest growing at this stage due to increasing manufacturing investments and infrastructure in the countries and the existing facilities, regulatory maturity, and ongoing cell therapy manufacturing ecosystems, respectively.
Latest Market News
Mar 19, 2026. One of the strongest biopharma leaders declared an innovation cell therapy production plant in Shanghai, investing more than USD 1 billion in the development of automated manufacturing and the rapid growth of equipment demands in the region.
Jan 08, 2026. A large equipment vendor partnered with a multinational CDMO to develop a strategic alliance to develop fully automated closed systems, aiming at reducing 25 percent of the number of manual steps in clinical scale processes.
Oct 14, 2025. A bioprocessing technology company introduced a second-generation bioreactor platform, which could expand from 2L to 200L and change cell expansion efficiency by about 40% in preliminary commercial operations.
Jun 27, 2025. One of the world's leading life sciences companies has successfully acquired one of the cell processing technology startups in a USD 275 million transaction, which has enhanced its hold on automated cell handling systems.
Mar 11, 2025. Multi-site validation program. The multi-site validation program started as a consortium of academic institutes and biotech firms of more than 50 manufacturing units to standardize closed-system workflows to minimize batch variability.
Dec 05, 2024. One of the CDMOs extended its footprint of cell therapy manufacturing with 120,000 square feet of cleanroom space and nearly 35% equipment installation capacity.
Aug 22, 2024. An equipment supplier in the U.S. had entered into a long-term supply contract with a European biotech firm to supply more than 150 automated units of cell processors to several facilities.
Feb 16, 2024. A regulatory agency presented new standards on the manufacturing of advanced therapies, and equipment vendors revised their systems to enhance their ability to comply with the standards and trace the production process.
Key Players
The Global Cell Therapy Manufacturing Equipment Market was valued at approximately USD 3.45 billion in 2025 and is projected to reach an estimated USD 6.82 billion by the end of 2030. Over the forecast period of 2026–2030, the market is expected to grow at a CAGR of around 14.6%.
The major drivers of the Global Cell Therapy Manufacturing Equipment Market include the accelerating clinical pipeline of cell therapies across oncology and regenerative medicine, increasing transition from clinical to commercial-scale manufacturing, and the rising adoption of automated and closed systems to improve reproducibility and contamination control. Additionally, growing outsourcing to CDMOs and the need for scalable, standardized manufacturing infrastructure are further driving market expansion.
Cell Processing Systems, Cell Expansion & Bioreactor Systems, Cell Separation & Sorting Equipment, Fill-Finish Equipment, Cryopreservation Equipment, and Others are the segments under the Global Cell Therapy Manufacturing Equipment Market by Equipment Type.
North America is the most dominant region for the Global Cell Therapy Manufacturing Equipment Market due to its advanced cell and gene therapy ecosystem, strong presence of biopharmaceutical companies and CDMOs, and significant investment in clinical and commercial manufacturing infrastructure. Additionally, established regulatory frameworks and high adoption of automated and closed systems further strengthen the region’s leading position.
Thermo Fisher Scientific Inc., Sartorius AG, Danaher Corporation, Merck KGaA, Lonza Group AG, Eppendorf AG, Getinge AB, Cytiva (Danaher Corporation), Miltenyi Biotec, Fresenius Kabi AG, Terumo Corporation, BD (Becton, Dickinson and Company), Bio-Techne Corporation, Avantor, Inc., and Corning Incorporated are key players in the Global Cell Therapy Manufacturing Equipment Market.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Specify your preferred Countries, Segments, or timeframes
Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.
